Taysha Gene Therapies Q4 Earnings Call Highlights

Taysha Gene Therapies (NASDAQ: TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a wider net loss for full-year 2025, according to management on the company's March 19 conference call. TSHA-102 development advances with FDA alignment and pivotal trial underway Chief Executive Officer